GS 6637

Drug Profile

GS 6637

Alternative Names: ANS-6637; GS-6637; GS-6673

Latest Information Update: 20 Feb 2017

Price : $50

At a glance

  • Originator Gilead Sciences
  • Developer Amygdala Neurosciences
  • Class Drug withdrawal therapies
  • Mechanism of Action Aldehyde dehydrogenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Drug abuse
  • Preclinical Alcoholism

Most Recent Events

  • 05 Jul 2017 Amygdala Neurosciences plans a phase I trial in Healthy volunteers (NCT03203499)
  • 16 Feb 2017 Amygdala Neurosciences acquires GS 6637 from Gilead Sciences
  • 16 Feb 2017 Phase-I clinical trials in Drug abuse in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top